Don't want to miss the best from Business Standard?
Used for topical treatment of actinic keratoses
Alembic Pharmaceuticals today announced that its wholly owned subsidiary, Aleor Dermaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diclofenac Sodium Topical Gel, 3%.The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Solaraze Topical Gel, 3%, of fougera Pharmaceuticals Inc. (Fougera).Diclofenac Sodium Topical Gel, 3% is indicated for the topical treatment of actinic keratoses. Sun avoidance is indicated during therapy. Diclofenac Sodium Topical Gel, 3% has an estimated market size of. US$10 million for twelve months ending Mar., 2022 according to IQVIA.
Powered by Capital Market - Live News
Make smarter market moves with The Smart Investor. Daily insights on buzzing stocks and actionable information to guide your investment decisions delivered to your inbox.
Disclaimer: No Business Standard Journalist was involved in creation of this content
